Oncology Channel
Breast Cancer
404 - Requested content not found
Please try to view another content
Select a Section
Next Up In Breast Cancer
SABCS 2023 Annual Meeting
MD /Alert Exclusives
Medscape Featured Breast Cancer Videos
Breaking Research
ASCO 2023 Annual Meeting
Curated For You
SABCS 2022 Annual Meeting
ASCO 2022 Annual Meeting
SABCS 2020 Annual Meeting
ASCO 2020 Annual Meeting
Next Up In Breast Cancer
3:50
LIVE FROM ASCO
HER3-DXd Promotes Clinical Activity in MBC at Varying HER3 Expression Levels
2:26
LIVE FROM ASCO
Donepezil Does Not Improve Cancer-Related Cognitive Impairment in Breast Cancer Survivors
2:46
MD /Alert Exclusive
Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive
2:42
MD /Alert Exclusive
Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer
2:07
LIVE FROM ASCO
Capecitabine Has Less Toxicity, Similar Survival in Metastatic Breast Cancer with Fixed Dose
MD /Alert Exclusive
ASCO, SSO Publish Guidelines for Germline Mutation Testing in Breast Cancer
2:42
MD /Alert Exclusive
Less Frequent Mammography for Breast Cancer Survivors Has No Impact on Survival
2:35
LIVE FROM ASCO
Greater Weight Loss Among Women with Breast Cancer After Phone-Based Coaching
2:30
MD /Alert Exclusive
Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation
2:50
MD /Alert Exclusive
Sacituzumab Govitecan Improves OS in Endocrine-Resistant Metastatic Breast Cancer
3:21
MD /Alert Exclusive
PET-CT Scanning Improves Detection of Metastases in Patients With Locally Advanced Breast Cancer
2:10
MD /Alert Exclusive
NCCN Clinical Practice Guidelines Recommend FES PET Imaging for ER+ Breast Cancer
2:50
MD /Alert Exclusive
Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery
3:20
MD /Alert Exclusive
Pertuzumab, Trastuzumab Combination Effective in HER2+ Metastatic Breast Cancer
2:20
LIVE FROM ASCO
Breast Cancer Index Risk Scores a Prognostic Indicator of Overall, Late Distant Recurrence
2:53
MD /Alert Exclusive
Chemotherapy Plus Treatment Combination for ERBB2-positive MBC Inferior in Clinical Practice
1:53
MD /Alert Exclusive
Olaparib Recommended for European Approval for Patients with High-Risk Early Breast Cancer
4:39
MD /Alert Exclusive
Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data
3:39
MD /Alert Exclusive
ASCO Guideline on Adjuvant Olaparib in Patients with HER2-negative Breast Cancer
2:45
MD /Alert Exclusive
Protein Coding Gene Enhances Cisplatin Resistance in Triple-Negative Breast Cancer
1:58
MD /Alert Exclusive
FDA Issues Warning Alert for Atezolizumab/Paclitaxel Combo in TNBC
6:11
Medscape
Providing Equitable Care in Early Breast Cancer
2:31
MD /Alert Exclusive
EU approves HER2+ Metastatic Breast Cancer Treatment
3:26
MD /Alert Exclusive
Abemaciclib Represents ‘New Standard of Care’ for Patients With High-Risk Early Breast Cancer
3:56
MD /Alert Exclusive
Camizestrant Improves PFS in Patients with HR+/HER2– Breast Cancer
2:02
MD /Alert Exclusive
Trastuzumab Deruxtecan Improves Survival in HER2-Positive Breast Cancer
2:31
MD /Alert Exclusive
Clinical Trials Need Better Representation Among Black Patients
3:48
MD /Alert Exclusive
Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer
1:51
WVU Medicine
Understanding Recent Breast Cancer Vaccine Breakthroughs
0:55
University of Maryland Medical Center
Oncologist Explains How Gammapod Works for Breast Cancer
3:04
MD /Alert Exclusive
Some Patients with Invasive Breast Cancer Can Skip Surgery
3:39
MD /Alert Exclusive
Atezolizumab Does Not Improve Pathologic Complete Response Rates in HER2+ Early Breast Cancer
1:29
MD /Alert Exclusive
FDA Rejects Breast Cancer Therapy Due to Safety Concerns
1:36
MD /Alert Exclusive
FDA Approves Companion Diagnostic for Patients with Breast Cancer, Low HER2 Expression
2:33
University of Shanghai Cancer Center
RNA TROJAN Promotes Triple-Negative Breast Cancer Progression
3:09
MD /Alert Exclusive
Combining Eribulin and Pembrolizumab in Metastatic Triple-Negative Breast Cancer
3:33
MD /Alert Exclusive
MINDACT Study Shows Continued Success in Determining Chemotherapy Usage
4:17
MD /Alert Exclusive
New ASCO, ASTRO, SSO Joint Clinical Guidelines for Hereditary Breast Cancer
4:30
MD /Alert Exclusive
Nitric Oxide Synthase Inhibitor Plus Taxane Show Promise in Chemoresistant TNBC
2:11
MD /Alert Exclusive
Durvalumab Provokes Robust Long-Term Outcomes in Patients with TNBC
5:58
Medscape
Neoadjuvant Opportunities in Early, High-Risk Breast Cancer
12:17
CDC
Improving Outcomes for Early Onset Breast Cancer
3:16
MD /Alert Exclusive
Ribociclib, Endocrine Therapy Combination Improves PFS in Aggressive Breast Cancer
1:19
MD /Alert Exclusive
FDA Approval in BRCA Mutated HER2-negative High-Risk Early Breast Cancer
3:06
MD /Alert Exclusive
Adjuvant Palbociclib Plus Endocrine Therapy Does Not Improve Outcomes in Patients with Breast Cancer
1:58
MD /Alert Exclusive
European Regulators Validate TNBC Biologic Treatment Application
3:28
MD /Alert Exclusive
Adjuvant Olaparib Significantly Improves Invasive DFS in Patients with High-Risk EBC, BRCA Mutations
3:48
MD /Alert Exclusive
Metformin Does Not Improve Disease-Free Survival in Early-Stage Breast Cancer Patients
2:36
MD /Alert Exclusive
Celecoxib Shows No Benefit for Patients with Early Breast Cancer
2:05
MD /Alert Exclusive
Endocrine Therapy Noninferior to Chemotherapy as First-Line Treatment for Patients with MBC
4:40
MD /Alert Exclusive
Mindfulness Shows Benefits for Young Breast Cancer
2:17
MD /Alert Exclusive
Ribociclib Plus Letrozole Shows Overall Survival Benefit in HR+/HER2- Advanced Breast Cancer
0:43
Walter and Eliza Hall Institute
Preventing Breast Cancer in Women Carrying BRCA1 Gene
3:02
MD /Alert Exclusive
New Test May Detect Multiple Cancers, Tumor Points of Origin
1:03
MD /Alert Exclusive
FDA Approves Biosimilar Treatment for Cancer-Related Neutropenia
2:46
MD /Alert Exclusive
Capivasertib, Fulvestrant Improves PFS in Patients with HR+/HER2– Breast Cancer
2:21
MD /Alert Exclusive
Researchers Identify Target of Metastasis in Triple-Negative Breast Cancer
1:37
University of Delaware
Why Dual Light Therapy Hits Triple Negative Breast Cancer Harder
3:30
MD /Alert Exclusive
Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes
3:45
MD /Alert Exclusive
Nobel Prize Winner Links Cancer Immunotherapy to Programmed Cell Death Gene
3:18
MD /Alert Exclusive
Treatment Combination Shows Promise in HR+, HER2–, HER2-mutant Metastatic Breast Cancer
2:48
MD /Alert Exclusive
NCCN Report Advises on Use of Pembrolizumab in Triple-Negative Breast Cancer
4:08
MD /Alert Exclusive
Study Shows Breastfeeding Can be Safe for Breast Cancer Survivors
2:44
MD /Alert Exclusive
ASCO Updates Guidelines for Pembrolizumab Treatment in Patients with Early-Stage TNBC
1:44
MD /Alert Exclusive
Olaparib Improves Survival in High Risk Early-Stage Breast Cancer
1:41
UT Southwestern Medical Center
Advancing Breast Cancer Care With Gammapod Radiation
1:51
MD /Alert Exclusive
FDA Approves Combo of Abemaciclib, Endocrine Therapy for Early Breast Cancer
1:25
MD /Alert Exclusive
Metastatic Breast Cancer Therapy Gains Fast Track Designation
2:35
MD /Alert Exclusive
Palbociclib Combination Fails to Extend Overall Survival for Advanced Breast Cancer
2:22
MD /Alert Exclusive
Lumpectomy, Mastectomy Result in Similar Outcomes in Younger Patients with Breast Cancer
3:58
Brigham and Women's Hospital
Overcoming Treatment Resistance in Breast Cancer
1:58
MD /Alert Exclusive
Sacituzumab Govitecan Extends Survival in Metastatic Triple-Negative Breast Cancer
1:25
MD /Alert Exclusive
FDA Clears First Clinical Trial for Breast Cancer Vaccine
2:17
MD /Alert Exclusive
Atezolizumab Withdrawn from FDA Accelerated Approval for TNBC
2:42
MD /Alert Exclusive
HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases
5:31
Medscape
Metastatic Breast Cancer: "The Journey Begins"
1:29
MD /Alert Exclusive
FDA Grants Fast Track Designation to Novel Treatment in Breast Cancer
3:18
MD /Alert Exclusive
Time to Treatment Completion Associated with Poor Breast Cancer Survival
2:34
MD /Alert Exclusive
No Benefit with Early Local Therapy In De Novo Metastatic Breast Cancer
1:41
National Cancer Institute
Various Breast Cancer Research Challenges in Recurrence, Triple Negative BC
1:36
MD /Alert Exclusive
FDA Approves Diagnostic to Identify Microsatellite Instability-High Solid Tumors
1:53
MD /Alert Exclusive
European Commission Approves Trastuzumab Deruxtecan for Second-Line HER2+ Breast Cancer
2:34
MD /Alert Exclusive
ASCO Issues Guidelines for Telemedicine in Oncology
2:06
MD /Alert Exclusive
FDA Accepts Biologics License Application for New Metastatic HER2+ Breast Cancer Treatment
3:29
MD /Alert Exclusive
ASCO Updates Guidelines for Patients with HER2+ Breast Cancer and Brain Metastasis
21:38
Dana Farber
Genomic Profiling Improves Metastatic Breast Cancer Research
3:52
MD /Alert Exclusive
Perioperative Combination Therapy Identifies Responders in Early HER2+ Breast Cancer
2:44
MD /Alert Exclusive
Pertuzumab-Based Regimen Continues to Reduce Recurrence in Patients with Early Breast Cancer
2:53
MD /Alert Exclusive
Trastuzumab Deruxtecan Highly Effective in Patients with HER2-Low Metastatic Breast Cancer
2:34
MD /Alert Exclusive
The Metastatic Spread of Breast Cancer Accelerates During Sleep
2:40
MD /Alert Exclusive
No OS Benefit with Margetuximab Over Trastuzumab in Previously Treated HER2+ Breast Cancer
4:26
Dana Farber
Study of Immunotherapy Combinations for Patients with Metastatic Breast Cancer
2:29
MD /Alert Exclusive
Treatment Combination Reduces Recurrence in Early-Stage Breast Cancer
1:31
MD /Alert Exclusive
FDA Grants Fast Track Designation in HR+/HER2- Metastatic Breast Cancer
1:46
MD /Alert Exclusive
FDA Grants Bria-IMT Immunotherapy for Metastatic Breast Cancer Fast Track Status
1:13
MD /Alert Exclusive
FDA Approves Trastuzumab Deruxtecan for HER2-Low Breast Cancer
3:38
MD /Alert Exclusive
ICI-Related Major Adverse Cardiac Events Rare, but Cause Significant Morbidity
4:37
MD /Alert Exclusive
Sacituzumab Govitecan Safe and Effective in Patients 65 and Older with TNBC
1:45
MD /Alert Exclusive
FDA Gives Priority Review for HR+, HER2– Advanced Breast Cancer Therapy
1:51
MD /Alert Exclusive
Large Epidemiology Study Updates Breast Cancer Risk for Women Lacking Family History
4:37
MD /Alert Exclusive
Therapy Targeting Inducible Nitric Oxide Signaling Shows Promise in TNBC
2:15
MD /Alert Exclusive
FDA Approves Sacituzumab Govitecan-hziy for Metastatic TNBC
3:57
MD /Alert Exclusive
Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer
1:20
MD /Alert Exclusive
FDA Approves AI Algorithms for Breast Cancer Detection
3:09
MD /Alert Exclusive
Inflammatory Markers May Predict Frailty After Chemotherapy
2:43
MD /Alert Exclusive
20-Year Benefit from Endocrine Therapy in Premenopausal Patients with Breast Cancer
4:43
MD /Alert Exclusive
Helping Breast Cancer Oncologists Work ‘In the Trenches’
5:37
Medscape
Integrating Tailored Therapy in Early, High-Risk Breast Cancer
2:17
MD /Alert Exclusive
Research Shows Benefits of Pembrolizumab as Single Agent TNBC Treatment
2:14
MD /Alert Exclusive
Results from BEATRICE and I–SPY2 Trials in TNBC and HR+/HER2- Breast Cancer
2:40
MD /Alert Exclusive
New Vaccine to Prevent Breast Cancer in Early Clinical Trials
1:51
MD /Alert Exclusive
Breast Cancer Clinical Trial Fails to Meet Primary Endpoint
3:34
MD /Alert Exclusive
Plasmid DNA Vaccine Shows Promise in Patients with Advanced-Stage ERBB2+ Breast Cancer
2:47
MD /Alert Exclusive
Oral Paclitaxel-Encequidar Superior to IV Paclitaxel in Metastatic Breast Cancer
2:29
MD /Alert Exclusive
Neoadjuvant Amcenestrant Shows Robust Response in Postmenopausal ER+/HER2- Breast Cancer
3:28
MD /Alert Exclusive
Zanidatamab-Docetaxel Effective as First-Line Therapy in Advanced HER2+ Breast Cancer
1:39
MD /Alert Exclusive
Pregnancy Does Not Worsen Outcomes in Triple-Negative Breast Cancer
2:21
MD /Alert Exclusive
Study Shows Tolerable Safety of Abemaciclib Plus Pembrolizumab in HER2-, Metastatic Breast Cancer
2:16
Bellvitge Biomedical Research Institute
New Uses for Existing Therapies in Breast Cancer Research
5:34
Medscape
Going the Distance With Metastatic Breast Cancer: "Personal Best"
2:39
MD /Alert Exclusive
Trastuzumab Deruxtecan Significantly Improves OS, PFS in Patients with MBC
2:25
MD /Alert Exclusive
FDA Committee Delays Approval of Pembrolizumab for Early TNBC
4:05
MD /Alert Exclusive
Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment
2:46
MD /Alert Exclusive
ASCO Updates Guidelines for Systemic Therapy in Advanced HER2+ Breast Cancer
2:00
MD /Alert Exclusive
Neratinib and Capecitabine Improves PFS in HER2+ Metastatic Breast Cancer
2:03
MD /Alert Exclusive
Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment
2:46
Trastuzumab Deruxtecan Lowers Risk of Progression in HER2+ Breast Cancer
SABCS 2023 Annual Meeting
2:42
MD /Alert Exclusive
Less Frequent Mammography for Breast Cancer Survivors Has No Impact on Survival
2:46
MD /Alert Exclusive
Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive
2:30
MD /Alert Exclusive
Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation
2:42
MD /Alert Exclusive
Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer
2:50
MD /Alert Exclusive
Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery
MD /Alert Exclusives
MD /Alert Exclusive
ASCO, SSO Publish Guidelines for Germline Mutation Testing in Breast Cancer
2:42
MD /Alert Exclusive
Less Frequent Mammography for Breast Cancer Survivors Has No Impact on Survival
2:46
MD /Alert Exclusive
Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive
2:30
MD /Alert Exclusive
Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation
2:42
MD /Alert Exclusive
Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer
2:50
MD /Alert Exclusive
Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery
2:50
MD /Alert Exclusive
Sacituzumab Govitecan Improves OS in Endocrine-Resistant Metastatic Breast Cancer
3:20
MD /Alert Exclusive
Pertuzumab, Trastuzumab Combination Effective in HER2+ Metastatic Breast Cancer
3:21
MD /Alert Exclusive
PET-CT Scanning Improves Detection of Metastases in Patients With Locally Advanced Breast Cancer
2:10
MD /Alert Exclusive
NCCN Clinical Practice Guidelines Recommend FES PET Imaging for ER+ Breast Cancer
3:56
MD /Alert Exclusive
Camizestrant Improves PFS in Patients with HR+/HER2– Breast Cancer
3:04
MD /Alert Exclusive
Some Patients with Invasive Breast Cancer Can Skip Surgery
2:40
MD /Alert Exclusive
No OS Benefit with Margetuximab Over Trastuzumab in Previously Treated HER2+ Breast Cancer
3:34
MD /Alert Exclusive
Plasmid DNA Vaccine Shows Promise in Patients with Advanced-Stage ERBB2+ Breast Cancer
2:39
MD /Alert Exclusive
Trastuzumab Deruxtecan Significantly Improves OS, PFS in Patients with MBC
3:16
MD /Alert Exclusive
Ribociclib, Endocrine Therapy Combination Improves PFS in Aggressive Breast Cancer
3:09
MD /Alert Exclusive
Inflammatory Markers May Predict Frailty After Chemotherapy
2:47
MD /Alert Exclusive
Oral Paclitaxel-Encequidar Superior to IV Paclitaxel in Metastatic Breast Cancer
1:45
MD /Alert Exclusive
FDA Gives Priority Review for HR+, HER2– Advanced Breast Cancer Therapy
1:36
MD /Alert Exclusive
FDA Approves Companion Diagnostic for Patients with Breast Cancer, Low HER2 Expression
3:02
MD /Alert Exclusive
New Test May Detect Multiple Cancers, Tumor Points of Origin
2:43
MD /Alert Exclusive
20-Year Benefit from Endocrine Therapy in Premenopausal Patients with Breast Cancer
3:39
MD /Alert Exclusive
Atezolizumab Does Not Improve Pathologic Complete Response Rates in HER2+ Early Breast Cancer
2:34
MD /Alert Exclusive
The Metastatic Spread of Breast Cancer Accelerates During Sleep
2:48
MD /Alert Exclusive
NCCN Report Advises on Use of Pembrolizumab in Triple-Negative Breast Cancer
2:44
MD /Alert Exclusive
Pertuzumab-Based Regimen Continues to Reduce Recurrence in Patients with Early Breast Cancer
1:13
MD /Alert Exclusive
FDA Approves Trastuzumab Deruxtecan for HER2-Low Breast Cancer
3:38
MD /Alert Exclusive
ICI-Related Major Adverse Cardiac Events Rare, but Cause Significant Morbidity
1:53
MD /Alert Exclusive
Olaparib Recommended for European Approval for Patients with High-Risk Early Breast Cancer
1:53
MD /Alert Exclusive
European Commission Approves Trastuzumab Deruxtecan for Second-Line HER2+ Breast Cancer
3:29
MD /Alert Exclusive
ASCO Updates Guidelines for Patients with HER2+ Breast Cancer and Brain Metastasis
2:29
MD /Alert Exclusive
Neoadjuvant Amcenestrant Shows Robust Response in Postmenopausal ER+/HER2- Breast Cancer
2:46
MD /Alert Exclusive
ASCO Updates Guidelines for Systemic Therapy in Advanced HER2+ Breast Cancer
3:18
MD /Alert Exclusive
Treatment Combination Shows Promise in HR+, HER2–, HER2-mutant Metastatic Breast Cancer
3:28
MD /Alert Exclusive
Zanidatamab-Docetaxel Effective as First-Line Therapy in Advanced HER2+ Breast Cancer
3:52
MD /Alert Exclusive
Perioperative Combination Therapy Identifies Responders in Early HER2+ Breast Cancer
1:03
MD /Alert Exclusive
FDA Approves Biosimilar Treatment for Cancer-Related Neutropenia
3:48
MD /Alert Exclusive
Metformin Does Not Improve Disease-Free Survival in Early-Stage Breast Cancer Patients
4:37
MD /Alert Exclusive
Sacituzumab Govitecan Safe and Effective in Patients 65 and Older with TNBC
1:20
MD /Alert Exclusive
FDA Approves AI Algorithms for Breast Cancer Detection
2:35
MD /Alert Exclusive
Palbociclib Combination Fails to Extend Overall Survival for Advanced Breast Cancer
2:45
MD /Alert Exclusive
Protein Coding Gene Enhances Cisplatin Resistance in Triple-Negative Breast Cancer
2:53
MD /Alert Exclusive
Trastuzumab Deruxtecan Highly Effective in Patients with HER2-Low Metastatic Breast Cancer
2:31
MD /Alert Exclusive
Clinical Trials Need Better Representation Among Black Patients
1:46
MD /Alert Exclusive
FDA Grants Bria-IMT Immunotherapy for Metastatic Breast Cancer Fast Track Status
3:06
MD /Alert Exclusive
Adjuvant Palbociclib Plus Endocrine Therapy Does Not Improve Outcomes in Patients with Breast Cancer
2:22
MD /Alert Exclusive
Lumpectomy, Mastectomy Result in Similar Outcomes in Younger Patients with Breast Cancer
2:44
MD /Alert Exclusive
ASCO Updates Guidelines for Pembrolizumab Treatment in Patients with Early-Stage TNBC
2:14
MD /Alert Exclusive
Results from BEATRICE and I–SPY2 Trials in TNBC and HR+/HER2- Breast Cancer
2:34
MD /Alert Exclusive
No Benefit with Early Local Therapy In De Novo Metastatic Breast Cancer
2:17
MD /Alert Exclusive
Ribociclib Plus Letrozole Shows Overall Survival Benefit in HR+/HER2- Advanced Breast Cancer
2:46
Trastuzumab Deruxtecan Lowers Risk of Progression in HER2+ Breast Cancer
2:46
MD /Alert Exclusive
Trastuzumab Deruxtecan Lowers Risk of Progression in HER2+ Breast Cancer
1:51
MD /Alert Exclusive
Breast Cancer Clinical Trial Fails to Meet Primary Endpoint
1:44
MD /Alert Exclusive
Olaparib Improves Survival in High Risk Early-Stage Breast Cancer
1:29
MD /Alert Exclusive
FDA Grants Fast Track Designation to Novel Treatment in Breast Cancer
2:21
MD /Alert Exclusive
Researchers Identify Target of Metastasis in Triple-Negative Breast Cancer
1:19
MD /Alert Exclusive
FDA Approval in BRCA Mutated HER2-negative High-Risk Early Breast Cancer
2:29
MD /Alert Exclusive
Treatment Combination Reduces Recurrence in Early-Stage Breast Cancer
2:34
MD /Alert Exclusive
ASCO Issues Guidelines for Telemedicine in Oncology
1:36
MD /Alert Exclusive
FDA Approves Diagnostic to Identify Microsatellite Instability-High Solid Tumors
1:39
MD /Alert Exclusive
Pregnancy Does Not Worsen Outcomes in Triple-Negative Breast Cancer
1:25
MD /Alert Exclusive
Metastatic Breast Cancer Therapy Gains Fast Track Designation
4:30
MD /Alert Exclusive
Nitric Oxide Synthase Inhibitor Plus Taxane Show Promise in Chemoresistant TNBC
2:06
MD /Alert Exclusive
FDA Accepts Biologics License Application for New Metastatic HER2+ Breast Cancer Treatment
1:31
MD /Alert Exclusive
FDA Grants Fast Track Designation in HR+/HER2- Metastatic Breast Cancer
2:40
MD /Alert Exclusive
New Vaccine to Prevent Breast Cancer in Early Clinical Trials
4:37
MD /Alert Exclusive
Therapy Targeting Inducible Nitric Oxide Signaling Shows Promise in TNBC
2:02
MD /Alert Exclusive
Trastuzumab Deruxtecan Improves Survival in HER2-Positive Breast Cancer
1:51
MD /Alert Exclusive
FDA Approves Combo of Abemaciclib, Endocrine Therapy for Early Breast Cancer
2:17
MD /Alert Exclusive
Atezolizumab Withdrawn from FDA Accelerated Approval for TNBC
2:36
MD /Alert Exclusive
Celecoxib Shows No Benefit for Patients with Early Breast Cancer
2:17
MD /Alert Exclusive
Research Shows Benefits of Pembrolizumab as Single Agent TNBC Treatment
2:53
MD /Alert Exclusive
Chemotherapy Plus Treatment Combination for ERBB2-positive MBC Inferior in Clinical Practice
3:39
MD /Alert Exclusive
ASCO Guideline on Adjuvant Olaparib in Patients with HER2-negative Breast Cancer
2:11
MD /Alert Exclusive
Durvalumab Provokes Robust Long-Term Outcomes in Patients with TNBC
2:05
MD /Alert Exclusive
Endocrine Therapy Noninferior to Chemotherapy as First-Line Treatment for Patients with MBC
3:28
MD /Alert Exclusive
Adjuvant Olaparib Significantly Improves Invasive DFS in Patients with High-Risk EBC, BRCA Mutations
2:15
MD /Alert Exclusive
FDA Approves Sacituzumab Govitecan-hziy for Metastatic TNBC
1:58
MD /Alert Exclusive
European Regulators Validate TNBC Biologic Treatment Application
1:29
MD /Alert Exclusive
FDA Rejects Breast Cancer Therapy Due to Safety Concerns
1:51
MD /Alert Exclusive
Large Epidemiology Study Updates Breast Cancer Risk for Women Lacking Family History
2:25
MD /Alert Exclusive
FDA Committee Delays Approval of Pembrolizumab for Early TNBC
1:25
MD /Alert Exclusive
FDA Clears First Clinical Trial for Breast Cancer Vaccine
4:43
MD /Alert Exclusive
Helping Breast Cancer Oncologists Work ‘In the Trenches’
4:17
MD /Alert Exclusive
New ASCO, ASTRO, SSO Joint Clinical Guidelines for Hereditary Breast Cancer
2:31
MD /Alert Exclusive
EU approves HER2+ Metastatic Breast Cancer Treatment
2:03
MD /Alert Exclusive
Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment
4:39
MD /Alert Exclusive
Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data
4:05
MD /Alert Exclusive
Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment
4:40
MD /Alert Exclusive
Mindfulness Shows Benefits for Young Breast Cancer
3:18
MD /Alert Exclusive
Time to Treatment Completion Associated with Poor Breast Cancer Survival
3:57
MD /Alert Exclusive
Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer
4:08
MD /Alert Exclusive
Study Shows Breastfeeding Can be Safe for Breast Cancer Survivors
3:26
MD /Alert Exclusive
Abemaciclib Represents ‘New Standard of Care’ for Patients With High-Risk Early Breast Cancer
1:58
MD /Alert Exclusive
Sacituzumab Govitecan Extends Survival in Metastatic Triple-Negative Breast Cancer
1:58
MD /Alert Exclusive
FDA Issues Warning Alert for Atezolizumab/Paclitaxel Combo in TNBC
3:45
MD /Alert Exclusive
Nobel Prize Winner Links Cancer Immunotherapy to Programmed Cell Death Gene
2:00
MD /Alert Exclusive
Neratinib and Capecitabine Improves PFS in HER2+ Metastatic Breast Cancer
3:33
MD /Alert Exclusive
MINDACT Study Shows Continued Success in Determining Chemotherapy Usage
3:48
MD /Alert Exclusive
Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer
3:30
MD /Alert Exclusive
Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes
2:42
MD /Alert Exclusive
HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases
Featured Breast Cancer Videos
5:58
Medscape
Neoadjuvant Opportunities in Early, High-Risk Breast Cancer
5:37
Medscape
Integrating Tailored Therapy in Early, High-Risk Breast Cancer
6:11
Medscape
Providing Equitable Care in Early Breast Cancer
5:34
Medscape
Going the Distance With Metastatic Breast Cancer: "Personal Best"
5:31
Medscape
Metastatic Breast Cancer: "The Journey Begins"
Breaking Research
5:16
Translational Genomics Research Institute
Personalized Assay Surpasses Limits for Detecting Tumor DNA in Breast Cancer Patients
3:58
Brigham and Women's Hospital
Overcoming Treatment Resistance in Breast Cancer
0:55
University of Maryland Medical Center
Oncologist Explains How Gammapod Works for Breast Cancer
1:41
UT Southwestern Medical Center
Advancing Breast Cancer Care With Gammapod Radiation
2:33
University of Shanghai Cancer Center
RNA TROJAN Promotes Triple-Negative Breast Cancer Progression
0:43
Walter and Eliza Hall Institute
Preventing Breast Cancer in Women Carrying BRCA1 Gene
ASCO 2023 Annual Meeting
2:26
LIVE FROM ASCO
Donepezil Does Not Improve Cancer-Related Cognitive Impairment in Breast Cancer Survivors
2:20
LIVE FROM ASCO
Breast Cancer Index Risk Scores a Prognostic Indicator of Overall, Late Distant Recurrence
3:50
LIVE FROM ASCO
HER3-DXd Promotes Clinical Activity in MBC at Varying HER3 Expression Levels
2:07
LIVE FROM ASCO
Capecitabine Has Less Toxicity, Similar Survival in Metastatic Breast Cancer with Fixed Dose
2:35
LIVE FROM ASCO
Greater Weight Loss Among Women with Breast Cancer After Phone-Based Coaching
Curated For You
21:38
Dana Farber
Genomic Profiling Improves Metastatic Breast Cancer Research
2:16
Bellvitge Biomedical Research Institute
New Uses for Existing Therapies in Breast Cancer Research
1:41
National Cancer Institute
Various Breast Cancer Research Challenges in Recurrence, Triple Negative BC
1:51
WVU Medicine
Understanding Recent Breast Cancer Vaccine Breakthroughs
4:26
Dana Farber
Study of Immunotherapy Combinations for Patients with Metastatic Breast Cancer
1:37
University of Delaware
Why Dual Light Therapy Hits Triple Negative Breast Cancer Harder
12:17
CDC
Improving Outcomes for Early Onset Breast Cancer
SABCS 2022 Annual Meeting
2:46
MD /Alert Exclusive
Capivasertib, Fulvestrant Improves PFS in Patients with HR+/HER2– Breast Cancer
3:56
MD /Alert Exclusive
Camizestrant Improves PFS in Patients with HR+/HER2– Breast Cancer
2:39
MD /Alert Exclusive
Trastuzumab Deruxtecan Significantly Improves OS, PFS in Patients with MBC
3:16
MD /Alert Exclusive
Ribociclib, Endocrine Therapy Combination Improves PFS in Aggressive Breast Cancer
ASCO 2022 Annual Meeting
1:13
MD /Alert Exclusive
FDA Approves Trastuzumab Deruxtecan for HER2-Low Breast Cancer
1:53
MD /Alert Exclusive
European Commission Approves Trastuzumab Deruxtecan for Second-Line HER2+ Breast Cancer
3:18
MD /Alert Exclusive
Treatment Combination Shows Promise in HR+, HER2–, HER2-mutant Metastatic Breast Cancer
3:28
MD /Alert Exclusive
Zanidatamab-Docetaxel Effective as First-Line Therapy in Advanced HER2+ Breast Cancer
4:37
MD /Alert Exclusive
Sacituzumab Govitecan Safe and Effective in Patients 65 and Older with TNBC
2:35
MD /Alert Exclusive
Palbociclib Combination Fails to Extend Overall Survival for Advanced Breast Cancer
2:53
MD /Alert Exclusive
Trastuzumab Deruxtecan Highly Effective in Patients with HER2-Low Metastatic Breast Cancer
2:31
MD /Alert Exclusive
Clinical Trials Need Better Representation Among Black Patients
SABCS 2020 Annual Meeting
2:25
MD /Alert Exclusive
FDA Committee Delays Approval of Pembrolizumab for Early TNBC
1:25
MD /Alert Exclusive
FDA Clears First Clinical Trial for Breast Cancer Vaccine
4:43
MD /Alert Exclusive
Helping Breast Cancer Oncologists Work ‘In the Trenches’
2:31
MD /Alert Exclusive
EU approves HER2+ Metastatic Breast Cancer Treatment
2:03
MD /Alert Exclusive
Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment
4:39
MD /Alert Exclusive
Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data
4:05
MD /Alert Exclusive
Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment
4:40
MD /Alert Exclusive
Mindfulness Shows Benefits for Young Breast Cancer
3:18
MD /Alert Exclusive
Time to Treatment Completion Associated with Poor Breast Cancer Survival
3:57
MD /Alert Exclusive
Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer
ASCO 2020 Annual Meeting
3:33
MD /Alert Exclusive
MINDACT Study Shows Continued Success in Determining Chemotherapy Usage
3:48
MD /Alert Exclusive
Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer
3:30
MD /Alert Exclusive
Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes
2:42
MD /Alert Exclusive
HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases
2:21
MD /Alert Exclusive
Study Shows Tolerable Safety of Abemaciclib Plus Pembrolizumab in HER2-, Metastatic Breast Cancer
3:09
MD /Alert Exclusive
Combining Eribulin and Pembrolizumab in Metastatic Triple-Negative Breast Cancer